BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ito N, Ohashi R, Nagata M. C3 glomerulopathy and current dilemmas. Clin Exp Nephrol 2017;21:541-51. [PMID: 27878657 DOI: 10.1007/s10157-016-1358-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Mizuno M, Suzuki Y, Ito Y. Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology. Clin Exp Nephrol 2018;22:3-14. [DOI: 10.1007/s10157-017-1405-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
2 Shin S, Seong Y, Lim BJ. Pathology of C3 Glomerulopathy. Child Kidney Dis 2019;23:93-9. [DOI: 10.3339/jkspn.2019.23.2.93] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Łukawska E, Polcyn-adamczak M, Niemir ZI. The role of the alternative pathway of complement activation in glomerular diseases. Clin Exp Med 2018;18:297-318. [DOI: 10.1007/s10238-018-0491-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
4 Lomzenski H, Thibodaux R, Guevara M. Complement your knowledge with a rare cause of pauci-immune glomerulonephritis. Clin Rheumatol 2018;37:3151-5. [PMID: 30203317 DOI: 10.1007/s10067-018-4275-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Asano M, Oda T, Mizuno M. A case of C3 glomerulopathy with nephritis-associated plasmin receptor positivity without a history of streptococcal infection. CEN Case Rep 2021. [PMID: 34799818 DOI: 10.1007/s13730-021-00662-2] [Reference Citation Analysis]
6 Mastrangelo A, Serafinelli J, Giani M, Montini G. Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood. Front Pediatr 2020;8:205. [PMID: 32478016 DOI: 10.3389/fped.2020.00205] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bergen AA, Arya S, Koster C, Pilgrim MG, Wiatrek-Moumoulidis D, van der Spek PJ, Hauck SM, Boon CJF, Emri E, Stewart AJ, Lengyel I. On the origin of proteins in human drusen: The meet, greet and stick hypothesis. Prog Retin Eye Res 2019;70:55-84. [PMID: 30572124 DOI: 10.1016/j.preteyeres.2018.12.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
8 Cao Q, Qi H, Yao L, Liu Q. Monoclonal gammopathy of renal significance: clinical manifestation, pathogenic characteristic and treatment. Panminerva Med 2020;62:38-53. [PMID: 30848114 DOI: 10.23736/S0031-0808.19.03609-7] [Reference Citation Analysis]
9 Andrighetto S, Leventhal J, Zaza G, Cravedi P. Complement and Complement Targeting Therapies in Glomerular Diseases. Int J Mol Sci 2019;20:E6336. [PMID: 31888179 DOI: 10.3390/ijms20246336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
10 Ahmad SB, Bomback AS. C3 Glomerulopathy: Pathogenesis and Treatment. Adv Chronic Kidney Dis 2020;27:104-10. [PMID: 32553242 DOI: 10.1053/j.ackd.2019.12.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
11 Snijders MLH, van de Wall-neecke BJ, Hesselink DA, Becker JU, Clahsen-van Groningen MC. Utility of immunohistochemistry with C3d in C3 glomerulopathy. Mod Pathol 2020;33:431-9. [DOI: 10.1038/s41379-019-0348-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Zuo C, Zhu Y, Xu G. An update to the pathogenesis for monoclonal gammopathy of renal significance. Ann Hematol 2020;99:703-14. [PMID: 32103323 DOI: 10.1007/s00277-020-03971-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Nakano M, Karasawa K, Moriyama T, Uchida K, Nitta K. Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center. Clin Exp Nephrol 2019;23:852-8. [PMID: 30854618 DOI: 10.1007/s10157-019-01716-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Zuo C, Zhu Y, Xu G. An update to the pathogenesis for monoclonal gammopathy of renal significance. Crit Rev Oncol Hematol 2020;149:102926. [PMID: 32199132 DOI: 10.1016/j.critrevonc.2020.102926] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Nakagawa N, Hasebe N, Hattori M, Nagata M, Yokoyama H, Sato H, Sugiyama H, Shimizu A, Isaka Y, Maruyama S, Narita I. Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol 2018;22:797-807. [PMID: 29214407 DOI: 10.1007/s10157-017-1513-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Drake KA, Ellington N, Gattineni J, Torrealba JR, Hendricks AR. Clinicopathological features of C3 glomerulopathy in children: a single-center experience. Pediatr Nephrol 2020;35:153-62. [PMID: 31667615 DOI: 10.1007/s00467-019-04388-3] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]